AI MARKET SCANNING

Aclaris Therapeutics, Inc.

📅 Next Catalyst: Nov 05, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.16%
MAX GAP RECORD -6.72%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ACRS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
-0.31%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
-2.41%
Feb 26, 2026 Earnings Release 2026-02-26 (BEFORE OPEN)
-4.23%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
+1.33%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
+0.00%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+0.78%
Feb 27, 2025 Earnings Release 2025-02-27 (BEFORE OPEN)
+3.33%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.2%
Bullish Gaps (6)
Bearish Gaps (3)
Neutral / Flat (5)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ACRS

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-28 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 264m +2.46%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗